Myovant Sciences→Sumitovant Biopharma (Sumitomo Pharma)
Acquisition · Cash + Stock · SMTOY · announced Oct 24, 2022
Announced
Oct 24, 2022
Closed
Mar 10, 2023
Economics
Cash + Stock()
Pre-deal · pre-deal mark: 2022, year precision · rounding grid ±$100M · Sumitovant press release — Myovant Sciences acquisition, 2023 (NYSE:MYOV market cap)
$27/share for outstanding minority (~$1.7B); total company value ~$2.9B fully diluted; Sumitovant already owned ~52%
Target
Myovant Sciences
Reproductive Health · Clinical / therapeutic
HQ Basel, Switzerland · Founded 2016
Women's health and oncology pharma — Myfembree (relugolix combo for uterine fibroids and endometriosis pain) and Orgovyx (prostate cancer); first oral GnRH antagonist combination approved for women's health
- Sumitomo Pharma press release (Oct 24, 2022)
- PR Newswire — Sumitovant announcement (Oct 2, 2022)
- Business Wire — completion announcement (Mar 10, 2023)
Acquirer
Sumitovant Biopharma (Sumitomo Pharma) (SMTOY)
Reproductive Health
HQ New York, NY
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Myfembree (relugolix combo) is first oral GnRH antagonist approved for uterine fibroids and endometriosis pain — combines with Orgovyx prostate cancer franchise under Sumitomo umbrella
Evidence ladder
Secondary (press / IR)
Sumitomo Pharma press release (Oct 24, 2022)
Secondary (press / IR)
Business Wire — completion announcement (Mar 10, 2023)
Limitations
- Citations are press/IR only — two wires of the same announcement are not dual-source. Add a primary filing.
- $27/share for outstanding minority (~$1.7B); total company value ~$2.9B fully diluted; Sumitovant already owned ~52%
- Pre-deal valuation sourced from: Sumitovant press release — Myovant Sciences acquisition, 2023 (NYSE:MYOV market cap). Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Reproductive Health
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer.
| Target | Acquirer | Announced | Value | Why included |
|---|---|---|---|---|
| Generate Life Sciences | CooperSurgical (CooperCompanies) | Nov 10, 2021 | value band |
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Target | Acquirer | Announced | Value | Vs this deal |
|---|---|---|---|---|
| Forendo Pharma | Organon | Nov 11, 2021 |
Patient empowerment context
Patient empowerment baseline (HLTH 2022)
No curated mapping — Myovant Sciences (Reproductive Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.
Research workspace (includes heuristic crosswalk) →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v9 · updated 2026-09-20 · 2 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.